Cheap Viagra On the Way

In this segment of the Motley Fool's Market Check-Up, Fool health-care analyst David Williamson takes investors through some of the biggest stories affecting Big Pharma, biotech stocks, and the health insurance industry today.

Pfizer has come to terms with generic drugmaker Teva Pharmaceuticals over its erectile dysfunction drug Viagra, with Teva due to launch its generic version two years early in 2017. As this will be earlier than Pfizer's patent expiration on the drug, Teva will be paying Pfizer an undisclosed royalty on sales, which should mitigate some of the damage the generic competitor would do. In this video, David tells investors why he thinks this is a great deal for Teva going forward, and talks about the most important catalyst for Pfizer investors on the horizon today.

Two game-changing biotechs
The best way to play the biotech space is to find companies that shun the status quo and, instead, discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report, "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.


The article Cheap Viagra On the Way originally appeared on Fool.com.

David Williamson owns shares of Pfizer. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.